No Harm, No Benefit from Maraviroc in Patients with Non-R5 HIV

The addition of maraviroc to optimized background therapy was well tolerated but conferred no virologic benefit in treatment-experienced patients with dual- or mixed-tropic virus.

Maraviroc, a CCR5 antagonist, is effective in treatment-experienced patients with R5-tropic HIV (JW AIDS Clin Care Sep 10 2007). In a manufacturer-funded trial, researchers assessed maraviroc’s safety and efficacy in patients with dual- or mixed-tropic virus (simply called “non-R5 virus”), viral loads ≥5000 copies/mL, and documented resistance to at least two classes of antiretroviral therapy (ART) or at least 3 months of experience receiving drugs in three ART classes. In all, 167 such patients were randomized to receive optimized background ART plus once-daily maraviroc, twice-daily maraviroc, or placebo. The primary endpoint was the change in plasma viral load at 24 weeks.

More than half the patients in each group discontinued treatment b…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

No Harm, No Benefit from Maraviroc in Patients with Non-R5 HIV

Topics

Reviewing Author